Compass Therapeutics, Inc. · Healthcare · Biotechnology
Scores & Status Key
AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$5.65
−$0.13 (−2.25%) 4:00 PM ET
Prev closePrevC$5.78
OpenOpen$5.87
Day highHigh$5.87
Day lowLow$5.62
VolumeVol3,322,439
Avg volAvgVol2,223,426
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$1.00B
P/E ratio
-12.56
FY Revenue
$0.00
EPS
-0.45
Sector
Healthcare
AI report sections
MIXED
CMPX
Compass Therapeutics, Inc.
Compass Therapeutics shows a pronounced upward price trend over the past year, with the latest close near the top of its 52-week range and above key moving averages. At the same time, the company remains loss-making with negative operating cash flow and relies on external financing, which introduces fundamental risk despite a sizable cash position. Short interest and short volume are elevated, indicating a meaningful level of skepticism or hedging against the recent strength.
AI summarized at 12:18 PM ET, 2026-01-14
AI summary scores
INTRADAY:72SWING:78LONG:46
Volume vs average
Intraday (cumulative)
+119% (Above avg)
Vol/Avg: 2.19×
RSI
41.78(Neutral)
Neutral (40–60)
0255075100
MACD momentum
Intraday
+0.00 (Strong)
MACD: 0.00 Signal: -0.00
Short-Term
-0.11 (Weak)
MACD: 0.01 Signal: 0.12
Long-Term
-0.08 (Weak)
MACD: 0.20 Signal: 0.28
Intraday trend score
40.66
LOW21.86HIGH47.86
Latest news
CMPX•12 articles•Positive: 5Neutral: 3Negative: 0
PositiveGlobeNewswire Inc.• Compass Therapeutics
Compass Therapeutics to Participate in Upcoming December Investor Events
Compass Therapeutics announced participation in two healthcare investor conferences in December 2025, highlighting their ongoing clinical-stage oncology research focused on antibody-based therapeutics targeting tumor growth and immune system interactions.
Company is presenting at multiple investor conferences, showing ongoing research progress in developing novel cancer treatment antibodies with promising preclinical data on CTX-10726 demonstrating tumor elimination in studies
PositiveGlobeNewswire Inc.• Compass Therapeutics
Compass Therapeutics to Participate in Upcoming September Investor Events
Compass Therapeutics will participate in multiple healthcare and investment conferences in September 2025, including events in Boston and New York, presenting their oncology-focused antibody-based therapeutics research.
Company is actively engaging with investors, presenting at multiple prestigious conferences, indicating confidence in their clinical-stage research and potential growth
NeutralGlobeNewswire Inc.• Compass Therapeutics
Compass Therapeutics Announces Pricing of Upsized $120 Million Public Offering
Compass Therapeutics plans to raise approximately $120 million through a public offering of 33,290,000 common stock shares and pre-funded warrants at $3.00 per share, with the proceeds intended for research, clinical development, and corporate purposes.
The company is conducting a standard public offering to raise capital for ongoing research and development, which is a typical financing strategy for clinical-stage biotech companies
NeutralBenzinga• Globe Newswire
Compass Therapeutics Announces Proposed Public Offering
Compass Therapeutics plans to launch an underwritten public offering of common stock and pre-funded warrants to fund research, clinical development, and commercial readiness preparations.
The company is seeking funding for research and development, which is a standard practice for clinical-stage biotech companies. The offering indicates a need for capital but does not inherently suggest positive or negative performance.
PositiveInvesting.com• Marketbeat.Com
Top 3 High-Momentum Companies Analysts Are Still Bullish On
Three companies with recent stock rallies that analysts remain bullish on are Compass Therapeutics, Amprius Technologies, and Allot Communications. Analysts see significant upside potential in these momentum stocks despite their recent gains.
Analysts have a consensus price target of $11.80, which is 266.5% above the current trading level, indicating significant upside potential despite the stock's recent 164% rally in the past year.
PositiveGlobeNewswire Inc.• N/A
Compass Therapeutics to Participate in Upcoming Investor Events
Compass Therapeutics, a clinical-stage biopharmaceutical company, announced its participation in two investor conferences in September 2024, where it will present updates on its oncology-focused pipeline of antibody-based therapeutics.
The article highlights Compass Therapeutics' participation in investor events, which suggests the company is actively engaging with the investment community and likely has positive developments to share about its pipeline and business.
NeutralGlobeNewswire Inc.• N/A
Eliem Therapeutics Announces Additions to its Leadership Team
Eliem Therapeutics announced the appointments of Brett Kaplan, M.D., as Chief Operating Officer, and Nishi Rampal, M.D., as Senior Vice President, Clinical Development. The new executives bring extensive experience in the pharmaceutical and biotechnology industries, which will help Eliem advance its pipeline of therapeutics for autoimmune-driven inflammatory diseases.
The article states that Brett Kaplan previously served as a director of Compass Therapeutics, Inc., but does not provide any additional details about the company.
PositiveGlobeNewswire Inc.• N/A
Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference
Compass Therapeutics, a clinical-stage biopharmaceutical company, announced that it will present at the Wedbush PacGrow Healthcare Conference on August 13, 2024. The company is developing proprietary antibody-based therapeutics to treat multiple human diseases, with a focus on the relationship between angiogenesis, the immune system, and tumor growth.
CMPXCompass TherapeuticsWedbush PacGrow Healthcare Conferenceoncologybiopharmaceuticalantibody-based therapeuticsangiogenesisimmune system
Sentiment note
The article presents Compass Therapeutics as a clinical-stage, oncology-focused biopharmaceutical company that is developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's focus on the relationship between angiogenesis, the immune system, and tumor growth suggests a promising approach to cancer treatment, which is reflected in the positive sentiment.
UnknownGlobeNewswire Inc.• Compass Therapeutics
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place in New York City, NY June 5 – 6, 2024.
CMPXCalendar of EventsConference Calls/ Webcasts
UnknownGlobeNewswire Inc.• Compass Therapeutics
Compass Therapeutics Announces CEO Transition
BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its Board of Directors has appointed Thomas Schuetz, M.D., Ph.D., President of Research and Development and Vice Chair of the Board of Directors of the Company, as President and Chief Executive Officer of the Company, effective May 28, 2024.
CMPXDirectors and OfficersManagement Changes
UnknownGlobeNewswire Inc.• Compass Therapeutics
Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced an upcoming poster presentation of its novel anti-CD137 agonist antibody, CTX-471, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies.
CMPXHealthClinical Study
UnknownGlobeNewswire Inc.• Compass Therapeutics
Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
BOSTON, May 14, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference taking place in New York City, NY on May 20, 2024.
CMPXCalendar of Events
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
